| |
IQVIA eCOA expert, Edward Bartels, walks through the capabilities and key features of the IQVIA eCOA platform. Watch the demo to explore functionalities from study design, eDiary and questionnaire design, and active study management.
|
|
Today’s Big NewsMay 17, 2024 |
| By James Waldron Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets while clearing space in its own pipeline and laying off 18% of its employees in the process. |
|
|
|
By Nick Paul Taylor Bayer’s master plan for its OASIS program is coming together, with the German drugmaker posting phase 3 data that suggest it could challenge Astellas for a recently unlocked menopause market. |
By Max Bayer,Gabrielle Masson Atai Life Sciences, one of the leading shareholders in psilocybin drug developer Compass Pathways, is swapping CEOs. |
By Kevin Dunleavy The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. With 18 of the industry’s top 25 companies achieving year-over-year revenue gains, Q1 came close to matching the final quarter of last year, when 21 of the top 25 companies showed increases. Once again, the dominant players were the sellers of GLP-1 diabetes and obesity drugs. |
|
Identify more unique genes with a rapid workflow (< 5 hrs) and inputs down to 1 ng. Explore the data.
|
|
By Angus Liu China-made PD-1 inhibitors continue to struggle at the FDA. This week, the U.S. agency rejected Elevar Therapeutics and Jiangsu Hengrui Pharma's PD-1 combination in liver cancer. |
By Ayla Ellison,Fraiser Kansteiner This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. |
By Conor Hale Thermo Fisher Scientific has put forward a DNA-based test it says can offer much more precise identification of blood and its compatibility. |
By Dave Muoio The Ohio-based health system touted "strong demand for both inpatient and outpatient services" but still had to contend with rising labor and supply spending during 2024's opening quarter. |
By Andrea Park AbbVie’s newest psoriasis awareness-raising campaign is taking the skin condition out of the spotlight. |
By Angus Liu Eisai has projected a significant sales increase for Leqembi. Takeda put down $100 million upfront for an option to license an anti-amyloid vaccine from AC Immune. The House oversight committee has voted overwhelmingly to advance a tweaked version of the BIOSECURE Act. And more. |
Fierce podcastsDon’t miss an episode |
| | This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
| WhitepaperPrecision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
| WhitepaperLearn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
| WhitepaperThis paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperDiscover the secrets behind successful patient engagement Sponsored by: ProofPilot |
| Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your copy today! Sponsored by: Sengenics Corporation LLC |
| Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download now to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by: Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
